M.D., Ph.D., Associate Chief Physician, Department of Gastrointestinal Oncology, Peking University Cancer Hospital; formerly concurrently served as the Aid-Tibet Director of the Oncology Department, Lhasa People's Hospital. Long-term engagement in standardized diagnosis and treatment, clinical research, and multidisciplinary comprehensive management of digestive system tumors, including gastric cancer, biliary tract tumors, pancreatic cancer, liver cancer, and colorectal cancer. Particularly accumulated extensive experience in molecular precision diagnosis and treatment of hepatobiliary and pancreatic tumors, optimization of AI-based treatment strategies, and individualized treatment models for tumors in high-altitude regions. In terms of social affiliations, currently serves as a member of the Biliary Tract Tumor Committee of the Chinese Society of Clinical Oncology (CSCO), Deputy Secretary-General of the Oncology Branch of the Chinese Geriatrics Society, and Standing Committee Member and Secretary-General of the Hepatobiliary and Pancreatic Clinical Research Branch of the Beijing Cancer Prevention and Treatment Society. Previously, as a member of the Beijing Aid-Tibet Medical Team, undertook the construction of the gastrointestinal tumor diagnosis and treatment system in the Lhasa region, the standardized establishment of multidisciplinary team (MDT) practices, and the development of a high-altitude regional tumor database. In research, has led and participated in multiple national, provincial, and ministerial-level projects, including the Beijing Municipal Science and Technology Commission project (AI direction, clinical cohort principal investigator), the Tibet Autonomous Region Natural Science Foundation Group Medical Aid-Tibet Project, and the Peking University Cancer Hospital Internal Innovation Project. Representative achievements include: 1. Large language model study for diagnosis and treatment prediction in gastric cancer, biliary tract tumors, and pancreatic cancer (Innovation Med, 2023); 2. Multimodal precision prediction model study for HER2-positive gastric cancer (Signal Transduct Target Ther, 2024); 3. Study on large language models in the management of gastrointestinal tumors (Medicine Plus, 2024); 4. Study on survival patterns and treatment models for gastric cancer patients in high-altitude regions (ongoing); 5. Clinical research and real-world practice on CLDN18.2, KRAS G12C/G12D targeted therapy and ADC advancements. Has received honors such as Peking University Outstanding Aid-Tibet Individual and Lhasa People's Hospital Outstanding Aid-Tibet Individual. Committed to advancing precision medicine for hepatobiliary and pancreatic tumors, AI-assisted clinical decision-making, and the construction of tumor prevention and treatment systems in high-altitude regions.